Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting

2024-512701-11-00 Systemic Juvenile Idiopathic Arthritis (sJIA) 4 2018-08-29
CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 All patients who have been treated with Novartis or Pen 5 2017-07-19
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Rheumatoid Arthritis 11 2016-03-30
GRAALL2014 Recruiting

2024-516103-16-00 Acute Lymphoblastic Leukemia (ALL) in younger adults (1 4 2015-12-04
A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without pso… Ended

2025-523051-64-00 Moderate to severe chronic plaque psoriasis 4 2026-01-26
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended

2024-519335-42-01 Systemic Sclerosis 4 2025-12-22
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US… Ended

2025-522345-21-00 Active psoriatic arthritis 1 2025-11-11
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended

2024-517524-18-00 Patients with moderate-to-severe allergic rhinitis / rh 10 2025-10-22
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy Ended

2024-517521-25-00 Patients with moderate-to-severe allergic rhinitis/rhin 10 2025-10-20
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of br… Ended

2024-520142-32-00 Cryopyrin associated periodic syndrome 1 2025-09-08
A study to evaluate the safety and tolerability of JNJ-90106848 and to investigate how long JNJ-90106848 stays in and acts on the body (phar… Ended

2025-521004-21-00 Inflammatory Conditions 1 2025-08-21
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 are Tolerated and Act in the Body in Healthy Adults Ended

2024-519215-33-00 IgA nephropathy 1 2025-08-07
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 4 2025-07-29
A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) Ended

2024-519095-66-00 Kidney Transplant Recipients with Late Antibody-Mediate 5 2025-07-23
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy Ended

2024-517515-75-00 Patients with moderate-to-severe allergic rhinitis / rh 10 2025-07-17
A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended

2024-519370-40-00 Alopecia areata 5 2025-07-16
Leniolisib for immune dysregulation in CVID Ended

2024-517725-93-00 Common variable immunodeficiency 4 2025-07-14
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Cutaneous lupus erythematosus 4 2025-07-11
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 ACPA-Positive Rheumatoid Arthritis 4 2025-06-23
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513266-19-00 Hidradenitis Suppurativa (HS) 5 2025-06-13